我武生物(300357) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥183,139,637.81, a decrease of 7.31% compared to the same period last year[8] - Net profit attributable to shareholders was ¥70,478,103.64, down 23.17% year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥67,924,569.47, a decrease of 11.48% compared to the previous year[8] - The company reported a total profit of ¥74,695,305.79, compared to ¥106,121,775.74 in the previous year, representing a decrease of 29.6%[33] - The net profit margin decreased to 36.2% from 46.4% year-over-year, highlighting a significant drop in profitability[33] - Basic and diluted earnings per share were both 0.1346, down from 0.1752 in the previous period[36] Cash Flow - The net cash flow from operating activities increased by 50.95% to ¥83,916,819.04 compared to the same period last year[8] - Cash inflow from operating activities totaled 233,270,208.98, slightly up from 229,210,561.85[36] - Net cash flow from operating activities increased to 83,916,819.04 from 55,592,478.71, representing a significant improvement[36] - Cash inflow from investment activities was 169,277,857.45, compared to 71,817,750.95 in the previous period[37] - Net cash flow from investment activities was -25,985,064.22, an improvement from -36,137,641.70[37] - Cash inflow from financing activities was 20,000,000.00, with net cash flow from financing activities at 18,155,668.39, compared to -1,029,911.15 previously[37] - The net increase in cash and cash equivalents was ¥57,660,630.02, reflecting a 313.03% increase compared to the same period last year[13] - The ending balance of cash and cash equivalents reached 486,872,767.67, compared to 298,128,769.36 at the end of the previous period[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,257,726,099.79, an increase of 2.72% from the end of the previous year[8] - The company's equity attributable to shareholders increased by 3.56% to ¥2,050,012,917.00 compared to the end of the previous year[8] - The company's total assets increased to ¥2,257,726,099.79 from ¥2,197,788,958.32, reflecting growth in financial stability[33] - The company's total liabilities decreased to RMB 163,682,765.73 from RMB 170,760,022.93, indicating a reduction of about 4.1%[24] - The company reported a decrease in accounts payable from RMB 7,682,719.29 to RMB 5,373,862.77, a decline of approximately 30.1%[24] - The company’s non-current liabilities increased slightly to RMB 69,759,246.60 from RMB 68,008,569.94, reflecting a growth of about 2.6%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,133, with the largest shareholder holding 38.86% of the shares[14] - The total equity attributable to shareholders increased to ¥2,050,012,917.00 from ¥1,979,540,771.28, showing a growth of 3.5%[33] Other Income and Investments - The company reported a significant decrease in other income, down 94.46% to ¥12,999,996.60, primarily due to reduced government subsidies related to daily operations[13] - The company reported an investment income of ¥2,468,267.68, significantly up from ¥674,438.30 in the previous year, indicating improved investment performance[33] Clinical Trials and Research - The company received a formal acceptance notice from the National Medical Products Administration for its clinical trial application of "Yanqumei Point Injection" in February 2023[21] - The company initiated a clinical study for its "Dermatitis Diagnostic Patch 01" with the first subject enrolled in February 2023[21] Inventory and Current Assets - Total current assets decreased to RMB 1,464,063,377.89 from RMB 1,477,132,637.58, indicating a decline of about 0.9%[22] - The company's inventory increased to RMB 50,605,440.56 from RMB 48,410,643.38, representing a growth of approximately 4.9%[22] Audit Information - The company did not undergo an audit for the first quarter report[38]